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Background: The most common reason why clinical trials fail is that they fall well below 
their goals for patient accrual. Researchers will frequently overpromise and underdeliver on 
the number of patients that they can recruit during the proposed time frame. The result is 
studies that take far longer than planned and/or that end with fewer patients than planned. 
This raises serious economic and ethical issues. Our research efforts have focused on (1) 
getting reliable data on the scope and magnitude of problems with slow patient accrual in 
clinical trials, and (2) developing a Bayesian model for accrual that will encourage careful 
planning of accrual rates as well as allow regular monitoring of accrual patterns during the 
conduct of the clinical trial. Methods: A random sample of 130 prospective studies 
approved by the Children's Mercy Hospital (CMH) IRB from 2001 through 2005 were 
retrospectively reviewed for the proposed and actual accrual rates. At the same time, a 
Bayesian model for accrual was developed and applied to a clinical trial at Kansas 
University Medical Center to produce monthly reports projecting estimated final sample 
sizes with uncertainty limits given the initial projection and currently available enrolment 
data. Results: 117 (90%) of the studies submitted to the IRB did not specify a start date, a 
completion date, or both, making it impossible to assess the accrual rate. Of the remaining 
studies, two failed to list actual start or end dates. Of the remaining 11 studies, 8 took more 
time than proposed and the average increase in duration in these 8 studies was 100%. 
Among the 109 studies that included both a target and an actual sample size, 59 (54%) fell 
short of the proposed sample size. The average shortfall across these 59 studies was 55%. 
The informative prior used in the Bayesian model was reasonable and produced early 
estimates of total sample size that were an accurate reflection of the end result. 
Conclusions: A large number of studies failed to meet the specified sample sizes and the 
average shortfall among these studies was considerable. The Bayesian model for accrual 
produced useful reports for a particular study and provided reassurance to the researchers 
that their accrual rates were on target. The Bayesian model, however, also has the 
capability of correcting an inaccurate  
prior distribution as the accumulated accrual patterns provide contradictory results. Future 
research should focus on collaborations with organizations that conduct large numbers of clinical 
trials to get more data on existing problems with slipped deadlines and sample size shortfalls and to 
test the Bayesian accrual model on a wide range of clinical trials 
